替格瑞洛联合阿托伐他汀治疗冠心病合并高脂血症患者的效果与安全性

doi:10.3969/j.issn.1671-7171.2026.08.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1185 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy and safety of ticagrelor combined with atorvastatin in patients with coronary heart disease (CHD) complicated with hyperlipidemia. 【Methods】 A total of 104 patients with CHD complicated with hyperlipidemia treated at Sanguanmiao Zhengshang Road Community Health Service Center, the Second Affiliated Hospital of Zhengzhou University from January 2023 to March 2025 were enrolled and divided into the control group (atorvastatin treatment) and the observation group (ticagrelor combined with atorvastatin treatment) by random number table method, with 52 cases in each group. Clinical efficacy, blood-lipid levels [high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), total cholesterol (TC)], cardiac function indicators [cardiac output, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDD)], laboratory indicators [vascular endothelial growth factor (VEGF), high-sensitivity C-reactive protein (hs-CRP), homocysteine (Hcy)] and incidence of adverse reactions were compared between the two groups. 【Results】 After 6-month follow-up, the total clinical effective rate of the observation group was 92.31% (48/52), which was higher than 76.92% (40/52) of the control group (χ²=4.727, P<0.05). After treatment, serum levels of LDL-C, TG and TC decreased, while serum HDL-C level increased in both groups (all P<0.05). There were no significant inter-group differences in HDL-C, LDL-C, TG and TC after treatment (all P>0.05). After treatment, cardiac output and LVEF increased, whereas LVDD decreased in both groups; the observation group had higher cardiac output and LVEF and lower LVDD compared with the control group (all P<0.05). After treatment, serum VEGF level increased, while hs-CRP and Hcy levels decreased in both groups. The observation group presented higher VEGF level and lower hs-CRP and Hcy levels than the control group (all P<0.05). The incidence of adverse reactions was 9.62% (5/52) in the observation group and 11.54% (6/52) in the control group, without statistically significant difference (χ²=0.102, P>0.05). 【Conclusion】 Ticagrelor combined with atorvastatin achieves favorable efficacy for patients with coronary heart disease complicated with hyperlipidemia. It can effectively improve cardiac function and enhance vascular repair capacity with good safety profile.

Key words： Coronary Disease Hyperlipidemias Ticagrelor Clopidogrel Atorvastatin

Received: 16 September 2025

PACS:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Xiaoli
	ZHU Suzhen
	LI Danli
	WANG Bo
	YANG Enbo

Cite this article:

ZHU Xiaoli,ZHU Suzhen,LI Danli, et al. Efficacy and Safety of Ticagrelor Combined with Atorvastatin in Patients with Coronary Heart Disease Complicated with Hyperlipidemia[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(8): 1249-1252.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.08.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I8/1249

[1] 彭丽华,李静,许婷媛. 依折麦布联合瑞舒伐他汀钙对老年冠心病伴高血脂症患者的临床疗效及心血管功能的影响[J]. 川北医学院学报,2023,38(11):1559-1562.
[2] 王霄,薛莉,常晶晶,等. 稳心降脂活血汤联合瑞舒伐他汀钙对冠心病并发高血脂患者内皮功能的影响[J]. 陕西中医,2022,43(7):872-875.
[3] 王文娟,李功辉,罗宇文. 不同剂量替格瑞洛联合阿托伐他汀钙片对冠心病UAP患者血液流变学心功能及血清MMP-9 IGF-1的影响[J]. 河北医学,2022,28(8):1383-1387.
[4] 檀崇斌,朱倩,甘成伟,等. 替格瑞洛联合阿托伐他汀与阿司匹林在急性冠状动脉综合症经皮冠状动脉介入术术后应用效果及安全性[J]. 临床军医杂志,2020,48(10):1243-1245.
[5] 郭晓艳,张翠英,吉锋. 解毒通脉胶囊治疗热毒痰瘀型冠心病合并高血脂症疗效观察[J]. 现代中西医结合杂志,2020,29(10):1053-1057.
[6] 中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志,2018,46(9):680-694.
[7] 中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会. 糖尿病合并高脂血症病证结合诊疗指南[J]. 世界中医药,2021,16(16):2377-2385.
[8] 曲政,尤斌,李平. 不同年龄段早发冠心病患者临床特征及危险因素的分析[J]. 心肺血管病杂志,2024,43(5):433-437.
[9] 甄胜达,张娜,张晓强,等. 依洛尤单抗对PCI术后血脂未达标的高脂血症冠心病患者脂代谢的影响[J]. 中南医学科学杂志,2024,52(5):843-845.
[10] 张科芝,张静,杨林飞,等. APOE基因与安徽地区冠心病血脂及冠脉病变程度的关系[J]. 现代科学仪器,2024,41(2):113-116.
[11] 刘潇,陈珮,杨伏肖,等. 老年冠心病住院患者合并其他疾病的分布及转归情况分析[J]. 中华老年心脑血管病杂志,2024,26(9):1090-1092.
[12] 李敏,朱浩,梅凌,等. 枳实薤白桂枝汤与他汀类药物对冠心病稳定型心绞痛合并高血脂症的二级预防作用探讨[J]. 广州中医药大学学报,2021,38(8):1583-1587.
[13] 王成龙,何新叶,李燕奇,等. 冠心病危险因素分析及机器学习算法构建预测模型研究[J]. 中国循证心血管医学杂志,2023,15(12):1334-1337.
[14] 王永民,张平,元晓敏. 替格瑞洛联合阿托伐他汀钙在冠心病患者PCI术后的应用价值[J]. 中国实用医刊,2022,49(6):100-103.
[15] 江丽华,关灵,黄嘉利,等. 阿托伐他汀钙联合替格瑞洛对冠心病高血脂患者的疗效和血清细胞因子的影响[J]. 中华肥胖与代谢病电子杂志,2021,7(3):165-169.